You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

A New Wave of Systemic Treatments: Atopic Dermatitis, Meet JAK

  • Authors: Melinda Gooderham, MSc, MD, FRCPC (Moderator); Brett King, MD, PhD; Kim Papp, MD, PhD, FRCPC
  • CME / CE Released: 3/11/2022
  • Valid for credit through: 3/11/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™

    Nurses - 1.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    Pharmacists - 1.25 Knowledge-based ACPE (0.125 CEUs)

    Physician Assistant - 1.25 AAPA hour(s) of Category I credit

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is designed for an audience of US-based dermatologists and allergists, physician assistants, pharmacists, and nurses who are involved in the care and treatment of patients with moderate to severe atopic dermatitis (AD).

The goal of this educational activity is to provide expert guidance to clinical learners on managing patients with AD.

Upon completion of this activity, participants will:

  • Interpret the efficacy and safety of current non-pharmacologic and pharmacologic treatments for AD and their limitations in long-term disease management
  • Summarize the mechanisms of action and evidence with new and emerging targeted immunomodulatory agents for long-term AD management
  • Develop individualized treatment plans for patients with moderate to severe AD that go beyond just treating flares and symptoms to optimize long-term control and overall quality of life
  • Apply best practices for vaccination of immunocompromised patients with AD


Disclosures

Disclosure of Conflicts of Interest

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclaimer This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Moderator

  • Melinda Gooderham, MSc, MD, FRCPC

    Medical Director, SKiN Centre for Dermatology
    Assistant Professor, Department of Medicine
    Queen’s University
    Kingston, Ontario, Canada
    Consultant Physician
    Peterborough Regional Health Centre
    Peterborough, Ontario, Canada

    Disclosures

    Melinda Gooderham, MSc, MD, FRCPC, has disclosed the following relevant financial relationships:
    Served as advisor for: AbbVie, Inc.; Actelion Pharmaceuticals; Amgen; Arena Pharmaceuticals; Asana Bio Sciences; Bausch Health; Boehringer Ingelheim International GmbH; Celgene Corporation; Dermavant; Eli Lilly and Company; Galderma SA; Janssen, Inc.; LEO Pharma; Novartis Pharmaceuticals; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharmaceuticals; UCB
    Served as consultant for: AbbVie, Inc.; Akros Pharma, Inc., Amgen; Bausch Health; Boehringer Ingelheim International GmbH; Celgene Corporation; Dermavant; Eli Lilly and Company; Janssen, Inc.; Kyowa Kirin; Novartis Pharmaceuticals; Sanofi Genzyme; Sun Pharmaceuticals; UCB
    Served as a contracted researcher for: AbbVie, Inc.; Akros Pharma, Inc.; Amgen; Arcutis Pharmaceuticals, Inc.; Bausch Health; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Celgene Corporation; Coherus Biosciences; Dermavant; Dermira, Inc.; Eli Lilly and Company; Galderma SA; GlaxoSmithKline; Glenmark; Janssen, Inc.; Kyowa Kirin; LEO Pharma; MedImmune; Merck and Co.; Novartis Pharmaceuticals; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Roche Laboratories; Sanofi Genzyme; Sun Pharmaceuticals; Takeda Pharmaceuticals; UCB
    Served as a speaker for: AbbVie, Inc.; Actelion Pharmaceuticals; Amgen; Bausch Health; Boehringer Ingelheim International GmbH; Celgene Corporation; Dermavant; Eli Lilly and Company; Galderma SA; Glenmark; Kyowa Kirin; LEO Pharma; Novartis Pharmaceuticals; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharmaceuticals; UCB

Faculty

  • Brett King, MD, PhD

    Associate Professor of Dermatology
    Yale University School of Medicine
    New Haven, Connecticut, United States

    Disclosures

    Brett King, MD, PhD, has disclosed the following relevant financial relationships:
    Served as advisor for: AbbVie, Inc.; AltruBio, Inc.; Almirall; Arena Pharmaceuticals; Bristol Myers Squibb; Eli Lilly and Company; Incyte Corp; Ostuska/Visterra Inc.; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Viela Bio
    Served as consultant for: AbbVie, Inc.; AltruBio, Inc.; Almirall; AnaptysBio; Arena Pharmaceuticals; Bioniz Therapeutics; Bristol Myers Squibb; Concert Pharmaceuticals; Horizon Therapeutics; Eli Lilly and Company; Incyte Corp; LEO Pharma; Otsuka/Visterra, Inc.; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; TWi Biotechnology, Inc.
    Served as speaker for: Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme

  • Kim Papp, MD, PhD, FRCPC

    President and Director of Research
    Probity Medical Research
    Waterloo, Ontario, Canada

    Disclosures

    Kim Papp, MD, PhD, FRCPC, has disclosed the following relevant financial relationships:
    Served as advisory board for: AbbVie, Inc.; Amgen; Astellas; Bausch Health/Valeant; Boehringer Ingelheim; Bristol Myers Squibb; Celgene Corporation; Dice Pharmaceuticals; Dow Pharma; Galderma; Janssen, Inc.; Merck Sharp & Dohme; Novartis Pharmaceuticals; PRCL Research; Regeneron Pharmaceuticals, Inc.; Sanofi-Aventis/Genzyme; Sun Pharma; UCB
    Served as consultant for: AbbVie, Inc.; Akros Pharma, Inc.; Amgen; Arcutis; Astellas; Avillion; Bausch Health/Valeant; Baxalta; Boehringer Ingelheim; Bristol Myers Squibb; Can-Fite Biopharma; Celgene; Celltrion; Coherus; Dermavant; Dermira; Dice Pharmaceuticals; Dow Pharma; Eli Lilly and Company; Evelo Biosciences; Forbion; Galapagos; Galderma; Genentech; Incyte; Janssen, Inc.; Kyowa Hakko Kirin; LEO Pharma; Meiji Seika Pharma; Merck Sharp & Dohme; Merck-Serono; Mitsubishi Pharma; Novartis Pharmaceuticals; Pfizer, Inc; PRCL Research; Regeneron Pharmaceuticals; Reistone; Roche; Sanofi-Aventis/Genzyme; Sandoz; Takeda; UCB; vTv Therapeutics; Xencor
    Received clinical research grants for: AbbVie, Inc.; Akros Pharma, Inc.; Amgen; Anacor; Arcutis; Astellas; Avillion; Bausch Health/Valeant; Baxalta; Boehringer Ingelheim; Bristol Myers Squibb; Can-Fite Biopharma; Celgene; Coherus; Dermavant; Dermira; Dow Pharma; Eli Lilly and Company; Evelo; Galapagos; Galderma; Genentech; Gilead; GlaxoSmithKline; Incyte; Janssen, Inc.; Kyowa Hakko Kirin; LEO Pharma; Medimmune; Merck-Serono; Merck Sharp & Dohme; Moberg Pharma; Novartis Pharmaceuticals; Pfizer, Inc.; PRCL Research; Regeneron Pharmaceuticals; Roche; Sanofi-Aventis/Genzyme; Sun Pharma; Takeda; UCB
    Served as scientific officer for: Akros; Anacor; Arcutis; Dice Pharmaceuticals; Kyowa Hakko Kirin
    Served as speakers bureau for: AbbVie; Amgen; Astellas; Bausch Health/Valeant; Can-Fite Biopharma; Eli Lilly; Galderma; Incyte; Janssen; Kyowa Hakko Kirin; LEO Pharma; Merck Sharp & Dohme; Novartis; Pfizer, Inc.; Sanofi-Aventis/Genzyme
    Served as steering committee for: AbbVie; Amgen; Bausch Health/Valeant; Boehringer Ingelheim; Celgene; Eli Lilly; Janssen; Kyowa Hakko Kirin; Merck-Serono; Merck Sharp & Dohme; Novartis; Pfizer, Inc.; PRCL Research; Sanofi-Aventis/Genzyme

Dorothy Caputo, MA, BSN, RN - AKH CE Director of Accreditations, has nothing to disclose.
Dorothy A. Duffy, RPh - AKH Pharmacy Reviewer, has nothing to disclose

Additional Planners/Reviewers Information and Disclosure Statements

AKH Planners and Reviewers have disclosed no relevant financial relationships.

AKH and LivDerm Planners and Reviewers have disclosed no relevant financial relationships. The content manager, Amy Kousouros, from LivDerm, has disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.


Accreditation Statements


In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

    For Nurses

  • 1.25 contact hours (0.0 contact hours are in the area of pharmacology)

    Contact This Provider

    For Pharmacists

  • AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 1.25 contact hour(s) (1.25 CEUs)

    Contact This Provider

  • For Physician Assistants

    AKH In., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 02/28/2023. PAs should only claim credit commensurate with the extent of their participation.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

A New Wave of Systemic Treatments: Atopic Dermatitis, Meet JAK

Authors: Melinda Gooderham, MSc, MD, FRCPC (Moderator); Brett King, MD, PhD; Kim Papp, MD, PhD, FRCPCFaculty and Disclosures

CME / CE Released: 3/11/2022

Valid for credit through: 3/11/2023

processing....

Pre-Assessment

Before you begin, please answer the questions in this brief questionnaire.

  • Print